Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 11/20 | 0.38 |
| ▸ | CCR5 | P51681 | 3/20 | 0.38 |
| ▸ | KDM1A | O60341 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.37 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.37 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.36 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.36 |
| ▸ | TACR1 | P25103 | 1/20 | 0.36 |
| ▸ | RORC | P51449 | 1/20 | 0.36 |
| ▸ | USP7 | Q93009 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3390583 | 0.92 | GPR119 (0.39) | GPR119CCR5KDM1AMAOBPRMT5 | |
| SCHEMBL3392388 | 0.90 | GPR119 (0.40) | GPR119CCR5KDM1AMAOBTACR1 | |
| SCHEMBL3395028 | 0.89 | CCR5 (0.40) | CCR5KDM1AMAOBPRMT5WDR77 | |
| SCHEMBL3395032 | 0.89 | CCR5 (0.40) | CCR5KDM1AMAOBPRMT5WDR77 | |
| Hydrochloric Acid SCHEMBL3394545 | 0.89 | CCR5 (0.39) | CCR5KDM1AMAOBPRMT5WDR77 | |
| Hydrochloric Acid SCHEMBL3394549 | 0.89 | CCR5 (0.39) | CCR5KDM1AMAOBPRMT5WDR77 | |
| SCHEMBL3389436 | 0.86 | CCR5 (0.51) | CCR5KDM1AMAOB | |
| Hydrochloric Acid SCHEMBL3394531 | 0.86 | CCR5 (0.50) | CCR5KDM1AMAOB | |
| SCHEMBL3393747 | 0.86 | CCR5 (0.41) | CCR5TACR1RORCUSP7 | |
| SCHEMBL3390772 | 0.85 | GPR119 (0.39) | GPR119CCR5KDM1AMAOBTACR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100286183-A1 | SPIROHYDANTOIN COMPOUNDS AND METHODS FOR THE MODULATION OF CHEMOKINE RECEPTOR ACTIVITY | CHAN CHUN KONG LAVAL | 2010-11-11 | — | — | US | claimed |
| US-7709642-B2 | Spirohydantoin compounds and methods for the modulation of chemokine receptor activity | VIROCHEM PHARMA, INC. (CA) | 2010-05-04 | — | — | US | claimed |
| US-20060014769-A1 | Spirohydantoin compounds and methods for the modulation of chemokine receptor activity | VIROCHEM PHARMA, INC. (CA) | 2006-01-19 | — | — | US | claimed |
| US-20100286183-A1 | SPIROHYDANTOIN COMPOUNDS AND METHODS FOR THE MODULATION OF CHEMOKINE RECEPTOR ACTIVITY | CHAN CHUN KONG LAVAL | 2010-11-11 | — | — | US | disclosed |
| US-20100286183-A1 | SPIROHYDANTOIN COMPOUNDS AND METHODS FOR THE MODULATION OF CHEMOKINE RECEPTOR ACTIVITY | CHAN CHUN KONG LAVAL | 2010-11-11 | — | — | US | disclosed |
| US-20100286183-A1 | SPIROHYDANTOIN COMPOUNDS AND METHODS FOR THE MODULATION OF CHEMOKINE RECEPTOR ACTIVITY | CHAN CHUN KONG LAVAL | 2010-11-11 | — | — | US | disclosed |
| US-7709642-B2 | Spirohydantoin compounds and methods for the modulation of chemokine receptor activity | VIROCHEM PHARMA, INC. (CA) | 2010-05-04 | — | — | US | disclosed |
| US-7709642-B2 | Spirohydantoin compounds and methods for the modulation of chemokine receptor activity | VIROCHEM PHARMA, INC. (CA) | 2010-05-04 | — | — | US | disclosed |
| US-7709642-B2 | Spirohydantoin compounds and methods for the modulation of chemokine receptor activity | VIROCHEM PHARMA, INC. (CA) | 2010-05-04 | — | — | US | disclosed |
| US-20060014769-A1 | Spirohydantoin compounds and methods for the modulation of chemokine receptor activity | VIROCHEM PHARMA, INC. (CA) | 2006-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060014769-A1 | Spirohydantoin compounds and methods for the modulation of chemokine receptor activity | CXCR1, CXCR2, CXCR4 | GPR119 249/4885CCR5 4/4885KDM1A 4354/4885 |
| US-20100286183-A1 | SPIROHYDANTOIN COMPOUNDS AND METHODS FOR THE MODULATION OF CHEMOKINE RECEPTOR ACTIVITY | CXCR1, CXCR2, CXCR4 | GPR119 249/4885CCR5 4/4885KDM1A 4354/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.